Tetrazanbigen
Tetrazanbigen is a potent and selective antitumor agent. Tetrazanbigen exhibits strong antitumor efficacy against six human cancer cell lines with an IC50 range of 2.13-8.01 μg/mL and an IC50 of 11.25 μg/mL against normal hepatocytes. Tetrazanbigen induces S phase arrest and apoptosis in QGY-7701 cells. Tetrazanbigen exerts its antitumor activity by inducing lipid accumulation accumulation in cancer cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2121990-04-1
- Formule: C18H16N4
- Masse moléculaire:288.35
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
9.65 μM
Compound: TNBG; 8g
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 33423463] |
| HepG2 | IC50 |
7.81 μM
Compound: TNBG; 8g
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 33423463] |
| LoVo | IC50 |
8.92 μM
Compound: TNBG; 8g
|
Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 33423463] |
Tetrazanbigen (0-12 μg/mL, 72 h) inhibits the proliferation of QGY-7701 cells, BIU-87 cells, Hep-2 cells, SGC-7901 cells, K562 cells, SW626 cells, and LO2 cells, with IC50 values of 2.13 μg/mL, 3.25 μg/mL, 3.84 μg/mL, 4.41 μg/mL, 7.70 μg/mL, 8.01 μg/mL, and 11.25 μg/mL, respectively[1].
Tetrazanbigen (0-8 μg/mL, 24-72 h) induces lipid accumulation in QGY-7701 cells[1].
Tetrazanbigen (2-4 μg/mL, 72 h) induces QGY-7701 cell cycle arrest at S phase and apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:QGY-7701 cells
-
Concentration:2 μg/mL, 4 μg/mL
-
Incubation Time:72 h
-
Result:Increased the population of S phase, decreased the populations of G0/G1 phases.
-
Cell Line:QGY-7701 cells
-
Concentration:4 μg/mL
-
Incubation Time:72 h
-
Result:Induced apoptosis, and caused condensed nuclei, apoptotic bodies and cellular shrinkage, chromatin margination.
Caused the appearance of a large number of lipid droplets.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice (Female athymic of 4 weeks old) bearing xenografts of QGY-7701 cell line (5 × 106, s.c.) [1]
-
Dosage:1.5 mg/kg/day
-
Administration:i.p., 5 weeks
-
Result:Reduced tumor volume and inhibited tumor weight, the TGI based on tumor weight was 87%.
Chemical Information
-
CAS No. 2121990-04-1
-
Masse moléculaire 288.35
-
Formule C18H16N4
-
SMILES
C1(N=C2N3CCC4=C(C=CC=C4)C3CN=C2N5)=C5C=CC=C1
-
Synonyms
TNBG
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tetrazanbigen Related Classifications
HY-176249 Related Classifications
Powered by Bioz